Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. - Wiethoff I; Witlox WJA; Evers SMAA; Michels M; Hiligsmann M (PharmacoEconomics, 2026)